(acetate or pamoate) is a gonadotropin-releasing hormone agonist
(GnRH agonist). By causing constant stimulation of the pituitary
, it decreases pituitary secretion of gonadotropins luteinizing hormone
(LH) and follicle stimulating hormone
(FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer
or breast cancer
, precocious puberty
-dependent conditions (such as endometriosis
or uterine fibroids
), and in assisted reproduction
. Triptorelin is marketed under the brand names Decapeptyl
) and Diphereline
. In the United States, it is sold by Pfizer
During the treatment of prostate cancer it does cause a surge of testosterone (an initial uplevel of testosterone levels), known as a flare effect. In men a reduction of serum testosterone levels into the range normally seen after surgical castration occurs approximately two to four weeks after initiation of therapy. In contrast, gonadotropin-releasing hormone antagonists do not cause a surge, but a sudden reduction of testosterone levels.
Systematic IUPAC Name: [d-Trp6]GnRH
- Lahlou N, Carel JC, Chaussain JL, Roger M (2000). "Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics". J Pediatr Endocrinol Metab 13 Suppl 1 723–37.
- Padula AM (2005). "GnRH analogues—agonists and antagonists". Anim Reprod Sci 88 (1-2): 115–26.